DocUpdate is a free HIPAA-compliant digital assistant built by physicians for physicians. Their tools, including an intelligent prescribing assistant, AI medical translator for 23+ languages, and pharmaceutical concierge, are designed to give clinicians time back. More at https://docupdate.onelink.me/j4xR/DermPCP

Last issue we took apart clean beauty and the idea that "natural versus synthetic" tells you anything useful about how a product will treat someone's skin.

This week we carry the same instinct to a different red, inflamed presentation, one that sends patients to urgent care and the hospital rather than back to the cosmetics aisle: the red, hot, swollen leg that gets called cellulitis and treated as cellulitis, whether or not that is what it is.

Cellulitis has no confirmatory test.

It is a pattern recognition diagnosis, and the pattern has a lot of impostors.

A meaningful share of the legs we treat with antibiotics are not infected at all, and a meaningful share of the ones that are infected get more antibiotic, more spectrum, and more days than the evidence supports.

The gap between how we tend to treat cellulitis and how the trials say we should is wide, and it is expensive for patients on both ends: undertreated mimics and overtreated infections.

The last few years of evidence point in one direction.

Get the diagnosis right first, then treat narrower, shorter, and by mouth when you can, and fix the reason it keeps coming back.

Concern for cellulitis drives roughly 2.8 million emergency department visits a year in the United States, and it is the most common dermatologic reason for hospital admission.

Yet when a dermatologist or infectious disease specialist reviews these cases, close to one in three lower-leg diagnoses turns out to be something other than cellulitis, a group of look-alikes collectively called pseudocellulitis.

Stasis dermatitis is the single most common impostor.

That misdiagnosis carries an estimated 195 to 515 million dollars in avoidable US spending each year, somewhere between 50,000 and 130,000 unnecessary hospitalizations, and about 44,000 courses of antibiotics given to people who never needed them (Weng et al., 2017). And for the patients who do have cellulitis, up to 47 percent will have another episode within three years (Webb et al., 2020).

Five habits turn a straightforward infection into a costly one. Here is each, and how to reset it.

The mistake: A patient presents with two red, swollen, warm lower legs. The reflex is cellulitis, and antibiotics start.

Why it happens: Red plus warm plus swollen reads as infection, and there is no blood test or scan to argue with the impression. Anchoring sets in fast. Stasis dermatitis, the most common mimic, produces the same erythema, warmth, and edema, so the two look alike at a glance.

The evidence: Roughly a third of diagnosed lower-extremity cellulitis is pseudocellulitis on specialist review (systematic review, J Gen Intern Med, 2023).

The most useful discriminator is simple: true cellulitis is almost always unilateral.

Bilateral, symmetric redness is far more likely to be venous stasis, contact or stasis dermatitis, or lipodermatosclerosis.

Asymmetry is also the heaviest-weighted variable in the validated ALT-70 prediction rule, which scores Asymmetry (3 points), Leukocytosis (1), Tachycardia (1), and age 70 or older (2).

A score of 0 to 2 carries an 83 percent or greater likelihood of a mimic; a score of 5 or more carries an 82 percent or greater likelihood of true cellulitis (Raff, Weng, Cohen et al., 2017).

Practical tip: Before you commit, run the quick differential out loud.

Bilateral, itchy, afebrile, chronic points away from infection.

When you are unsure, the ALT-70 (free on MDCalc) gives you a defensible number rather than a hunch, and a low score is a prompt to treat the dermatitis and hold the antibiotics.

The mistake: Writing for 10 to 14 days out of habit, then extending when the leg still looks red at follow-up.

Why it happens: Longer courses feel safer, and residual erythema at day 5 gets read as ongoing infection rather than resolving inflammation.

The evidence: In a randomized, double-blind, placebo-controlled trial, 5 days of antibiotic worked as well as 10 for uncomplicated cellulitis, with a 98 percent success rate in both arms (Hepburn et al., 2004).

The IDSA skin and soft tissue guideline recommends 5 days and extending only if the infection has not improved (Stevens et al., 2014).

NICE and the American College of Physicians land in the same 5-to-6-day range and frame longer courses as an avoidable driver of resistance and side effects (ACP best practice advice, Ann Intern Med, 2021).

Erythema that lingers after a few days is often residual inflammation, the skin equivalent of a chest film that stays abnormal after pneumonia clears, not a signal to keep dosing.

Practical tip: Prescribe 5 to 6 days for uncomplicated cellulitis and reassess at 48 to 72 hours. Extend only if the patient is not clearly improving, meaning spreading borders, rising fever, or worsening pain.

Tell the patient at the first visit that the redness may take longer to fade than the infection takes to resolve, so a still-pink leg on day 5 does not mean the antibiotic failed.

The mistake: Starting intravenous antibiotics or admitting a stable patient who could be treated at home with pills.

Why it happens: IV feels stronger and more definitive, and a bright red leg feels like it warrants the hospital.

The evidence: For stable patients without systemic toxicity, oral antibiotics are as effective as IV for most cellulitis, and oral therapy avoids line complications, hospital-acquired infection, and cost (Therapeutics Initiative review, 2025).

IDSA reserves parenteral therapy for patients with signs of systemic inflammatory response, hemodynamic instability, immunocompromise, facial involvement, or failure of oral treatment (Stevens et al., 2014).

Where IV access or daily infusions have been the barrier to discharge, single-dose long-acting lipoglycopeptides such as dalbavancin are now being used through emergency department pathways, and early real-world implementation data show reduced admissions for cellulitis (Munson Medical Center pathway, IDWeek/OFID abstract, 2024 to 2025).

Practical tip: Absent SIRS, instability, immunocompromise, or an inability to tolerate oral intake, treat orally at home with follow-up in 48 to 72 hours.

Mark the border of erythema with a skin-safe pen or photograph it so the patient and the next clinician can see whether it is advancing or retreating.

The mistake: Adding trimethoprim-sulfamethoxazole or doxycycline to a beta-lactam "just in case" for a nonpurulent, uncomplicated cellulitis.

Why it happens: Two decades of community-acquired MRSA have trained a broad-coverage reflex, and it can feel negligent to leave MRSA uncovered.

The evidence: Nonpurulent cellulitis without an abscess is predominantly a streptococcal infection, and covering MRSA does not improve outcomes.

In a 500-patient randomized trial, cephalexin plus trimethoprim-sulfamethoxazole was no better than cephalexin alone (83.5 versus 85.5 percent cure in the per-protocol analysis), and the authors concluded that routine MRSA-targeted therapy is not needed for nonpurulent disease (Moran et al., 2017).

IDSA directs streptococcal coverage for nonpurulent cellulitis and reserves MRSA-active agents for purulent infection and abscess (Stevens et al., 2014).

Adding a second drug adds diarrhea, drug interactions, and resistance pressure without a cure benefit.

Practical tip: For nonpurulent cellulitis, a beta-lactam is first line: cephalexin, dicloxacillin, or penicillin. Save MRSA coverage for purulent cellulitis or abscess, penetrating trauma, known MRSA colonization or history, or systemic toxicity. Purulence is the signal that changes the drug, not the redness itself.

The mistake: Clearing the infection and stopping there, without touching the reasons this patient will be back.

Why it happens: Recurrence shows up weeks later, often to a different clinician, so the portal of entry and the chronic edema never get examined during the acute visit.

The evidence: Recurrence is common, up to 47 percent within three years, and two of the biggest drivers are both treatable.

Tinea pedis and toe-web intertrigo create a bacterial portal of entry between the toes and are strongly associated with lower-limb cellulitis (Björnsdóttir et al., 2005).

Chronic leg edema is the other engine, and it responds to compression: in a randomized trial in patients with chronic edema and recurrent cellulitis, compression therapy cut recurrence by 77 percent, a larger effect than antibiotic prophylaxis has ever shown, and the trial was stopped early for benefit (Webb et al., 2020).

Prophylactic penicillin also works while it is being taken, reducing recurrence by roughly half, though the protective effect fades once the drug stops (Thomas et al., PATCH I, 2013).

Practical tip: Make three checks part of every cellulitis visit. Look between the toes and treat tinea pedis with a topical antifungal, since the athlete's foot is often the front door. Address chronic edema with compression once infection is controlled, DVT is excluded, and arterial supply is adequate.

For a patient with two or more episodes a year, discuss low-dose penicillin V prophylaxis with a clear conversation that the benefit lasts as long as the prophylaxis does.

Cellulitis is where antibiotic stewardship and dermatologic accuracy meet in the same red leg. The direction of the evidence is consistent: fewer people need antibiotics than we treat, and the people who do need them generally need a narrower drug, for fewer days, by mouth, at home.

The value we add is not a stronger prescription but a correct diagnosis, a right-sized course, and attention to the portal of entry and the edema that will otherwise send the patient back.

One area to watch is adjunctive anti-inflammatory treatment. IDSA already notes that a short course of systemic corticosteroids alongside antibiotics can speed clinical improvement in nondiabetic adults, without raising relapse, and dedicated trials of adjunctive steroids for limb cellulitis are underway.

It is not yet routine practice, but it is a reasonable thing to know is coming as you counsel patients on what "getting better" should look like.

Interested in reaching our 8,000+ subscribers?

Click here to learn more!

https://go.dermforprimarycare.com/newsletter-sponsor-lp 

We have created this FREE Guide for you:

Take one of our modules!

The red leg is a quiet test of discipline. Most of the time the better outcome comes from a closer look rather than a stronger prescription: one leg or two, purulent or not, and what is happening in the skin between the toes.

Get that right and you spare a lot of patients an admission they never needed and a course of antibiotics they were never going to benefit from.

Next week we turn from restraint to enthusiasm and take on microneedling, a treatment patients now request by name, convinced it will erase scars and years. We will separate what the needles actually do from what the marketing promises, and hand you the version worth repeating in the exam room.

See you then!

Have a topic you'd like us to cover? Reply to this email.

DERM Community | Derm for Primary Care Team